Cingulate Inc (CING)

$4.14 -0.20 (-4.49%)
Market Cap 53.34M
Revenue (ttm) 0.00
Net Income (ttm) -22.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,011,419
Avg Vol 539,182
Day's Range N/A - N/A
Shares Out 13.47M
Stochastic %K 36%
Beta -0.81
Analysts Strong Sell
Price Target $23.60

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
Sausty
Sausty May. 29 at 8:20 PM
$CING
0 · Reply
alwaysbuylate
alwaysbuylate May. 29 at 8:19 PM
$CING now...it's getting weird. No update?
2 · Reply
Wealthy500
Wealthy500 May. 29 at 7:28 PM
$CING i think approval coming. Got a feeling. Lets see what happens.
1 · Reply
cubie
cubie May. 29 at 7:27 PM
$CING sorry giddy bulls😅
0 · Reply
Junior31
Junior31 May. 29 at 7:17 PM
$CING Back in for the CRL. Short 9,500 shares @ $4.25
1 · Reply
jimmy18000
jimmy18000 May. 29 at 7:11 PM
$CING thanks for sharing. Do you have a meeting with them today? Show us some pics and we can handicap if approved or not 😅. traders have less than an hr to exit, decrease their exposure or ride it out and increase their postion till decision…was thinking if approved, we should have been halted by now.
2 · Reply
SamMusaX
SamMusaX May. 29 at 7:06 PM
$CING
4 · Reply
SamMusaX
SamMusaX May. 29 at 7:02 PM
$CING 🤗
0 · Reply
SamMusaX
SamMusaX May. 29 at 7:01 PM
$CING more pics coming
0 · Reply
SamMusaX
SamMusaX May. 29 at 6:47 PM
$CING As promised...
1 · Reply
Latest News on CING
Cingulate Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 9 hours ago

Cingulate Proxy statement: Proxy filing

Cingulate Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 9 hours ago

Cingulate Proxy statement: Proxy filing

Cingulate price target lowered to $10 from $14 at Roth Capital

2026-05-19T15:00:40.000Z - 10 days ago

Cingulate price target lowered to $10 from $14 at Roth Capital

Cingulate Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 11 days ago

Cingulate Proxy statement: Proxy filing

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

May 14, 2026, 8:00 AM EDT - 15 days ago

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 15 days ago

Cingulate Earnings release: Q1 2026

Cingulate Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 15 days ago

Cingulate Quarterly report: Q1 2026

Cingulate files to sell 4.21M shares of common stock for holders

2026-04-14T21:30:17.000Z - 6 weeks ago

Cingulate files to sell 4.21M shares of common stock for holders

Cingulate Registration statement: Registration filing

Apr 14, 2026, 8:00 AM EDT - 6 weeks ago

Cingulate Registration statement: Registration filing

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Apr 6, 2026, 4:34 PM EDT - 7 weeks ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Cingulate Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 2 months ago

Cingulate Slides: Corporate presentation

Cingulate Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Cingulate Registration statement: Registration filing

Cingulate price target lowered to $14 from $16 at Roth Capital

2026-03-22T22:30:08.000Z - 2 months ago

Cingulate price target lowered to $14 from $16 at Roth Capital

Cingulate Registration statement: Registration filing

Mar 20, 2026, 8:00 AM EDT - 2 months ago

Cingulate Registration statement: Registration filing

Cingulate files to sell 3.5M shares of common stock for holders

2026-03-20T11:46:09.000Z - 2 months ago

Cingulate files to sell 3.5M shares of common stock for holders

Cingulate announces U.S. patent notice of allowance

2026-03-18T12:12:11.000Z - 2 months ago

Cingulate announces U.S. patent notice of allowance

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

2026-03-18T12:05:55.000Z - 2 months ago

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

Cingulate sees cash runway into late 4Q26

2026-03-18T12:05:40.000Z - 2 months ago

Cingulate sees cash runway into late 4Q26

Cingulate Proxy statement: Proxy Filing

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Cingulate Earnings release: Q4 2025

Cingulate Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Cingulate Annual report: Q4 2025

Why did Cingulate stock skyrocket today?

Mar 16, 2026, 1:26 PM EDT - 2 months ago

Why did Cingulate stock skyrocket today?

Cingulate Proxy statement: Proxy Filing

Mar 2, 2026, 7:00 AM EST - 3 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Feb 18, 2026, 7:00 AM EST - 3 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate files $200M mixed securities shelf

2026-01-12T22:15:20.000Z - 4 months ago

Cingulate files $200M mixed securities shelf

Cingulate Registration statement: Registration Filing

Jan 12, 2026, 7:00 AM EST - 4 months ago

Cingulate Registration statement: Registration Filing

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T12:40:10.000Z - 6 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T00:55:07.000Z - 6 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Nov 18, 2025, 4:27 PM EST - 6 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

2025-11-13T13:16:41.000Z - 7 months ago

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

Cingulate Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Cingulate Quarterly report: Q3 2025

Cingulate Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Cingulate Earnings release: Q3 2025

Cingulate names Downey as CCO to lead launch prep for CTx-1301

2025-11-10T13:25:38.000Z - 7 months ago

Cingulate names Downey as CCO to lead launch prep for CTx-1301

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

2025-10-28T12:27:02.000Z - 7 months ago

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 7 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate price target raised to $17 from $10 at Roth Capital

2025-10-15T01:25:08.000Z - 8 months ago

Cingulate price target raised to $17 from $10 at Roth Capital

Cingulate announces FDA accepted for review the NDA for CTx-1301

2025-10-14T12:05:41.000Z - 8 months ago

Cingulate announces FDA accepted for review the NDA for CTx-1301

Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences

2025-09-17T12:50:16.000Z - 9 months ago

Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 9 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 10 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate price target lowered to $10 from $11 at Roth Capital

2025-08-20T21:40:18.000Z - 10 months ago

Cingulate price target lowered to $10 from $11 at Roth Capital

Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year

2025-08-19T12:50:08.000Z - 10 months ago

Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 10 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Quarterly report: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 10 months ago

Cingulate Quarterly report: Q2 2025

Cingulate Earnings release: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 10 months ago

Cingulate Earnings release: Q2 2025

Cingulate places CEO Schaffer on administrative leave

2025-08-15T13:10:52.000Z - 10 months ago

Cingulate places CEO Schaffer on administrative leave

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 10 months ago

Cingulate Provides Management Team Update

Cingulate Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 10 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 10 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Jul 22, 2025, 8:00 AM EDT - 11 months ago

Cingulate Registration statement: Registration Filing

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 1 year ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Cingulate Earnings release: Q1 2025

Cingulate Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Cingulate Quarterly report: Q1 2025

Cingulate Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Annual report: Q4 2024

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Cingulate Annual report: Q4 2024

Cingulate Earnings release: Q4 2024

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Cingulate Earnings release: Q4 2024

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cingulate Quarterly report: Q3 2024

Cingulate Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cingulate Earnings release: Q3 2024

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Registration statement: Registration Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Sep 27, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate Proxy statement: Proxy Filing

Aug 23, 2024, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Cingulate Quarterly report: Q2 2024

Cingulate Earnings release: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Cingulate Earnings release: Q2 2024

Cingulate Proxy statement: Proxy Filing

Jul 22, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 2 years ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate Proxy statement: Proxy Filing

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 2 years ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 2 years ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Proxy statement: Proxy Filing

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Cingulate Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Quarterly report: Q1 2024

Cingulate Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q1 2024

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 2 years ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 2 years ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Cingulate Annual report: Q4 2023

Cingulate Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q4 2023

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Cingulate Registration statement: Registration Filing

Jan 29, 2024, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate Registration statement: Registration Filing

Jan 12, 2024, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Registration statement: Registration Filing

Nov 15, 2023, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Cingulate Quarterly report: Q3 2023

Cingulate Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Cingulate Earnings release: Q3 2023

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Proxy statement: Proxy Filing

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Sep 22, 2023, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Cingulate Registration statement: Registration Filing

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Registration statement: Registration Filing

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Aug 22, 2023, 8:00 AM EDT - 3 years ago

Cingulate Registration statement: Registration Filing

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 3 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Cingulate Quarterly report: Q2 2023

Cingulate Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Cingulate Earnings release: Q2 2023

Cingulate Registration statement: Registration Filing

Jul 25, 2023, 8:00 AM EDT - 3 years ago

Cingulate Registration statement: Registration Filing

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 3 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Sausty
Sausty May. 29 at 8:20 PM
$CING
0 · Reply
alwaysbuylate
alwaysbuylate May. 29 at 8:19 PM
$CING now...it's getting weird. No update?
2 · Reply
Wealthy500
Wealthy500 May. 29 at 7:28 PM
$CING i think approval coming. Got a feeling. Lets see what happens.
1 · Reply
cubie
cubie May. 29 at 7:27 PM
$CING sorry giddy bulls😅
0 · Reply
Junior31
Junior31 May. 29 at 7:17 PM
$CING Back in for the CRL. Short 9,500 shares @ $4.25
1 · Reply
jimmy18000
jimmy18000 May. 29 at 7:11 PM
$CING thanks for sharing. Do you have a meeting with them today? Show us some pics and we can handicap if approved or not 😅. traders have less than an hr to exit, decrease their exposure or ride it out and increase their postion till decision…was thinking if approved, we should have been halted by now.
2 · Reply
SamMusaX
SamMusaX May. 29 at 7:06 PM
$CING
4 · Reply
SamMusaX
SamMusaX May. 29 at 7:02 PM
$CING 🤗
0 · Reply
SamMusaX
SamMusaX May. 29 at 7:01 PM
$CING more pics coming
0 · Reply
SamMusaX
SamMusaX May. 29 at 6:47 PM
$CING As promised...
1 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers May. 29 at 6:38 PM
$CING Now short 10,000 shares See you all Monday CRL should drop this to 1 buck
6 · Reply
BrokeUntilFriday
BrokeUntilFriday May. 29 at 6:34 PM
$CING Support held. VWAP was reclaimed. Momentum improved. The chart looks constructive, but the FDA decision is still the only catalyst that truly matters. Everything else is just positioning ahead of the answer.
1 · Reply
FCZ04
FCZ04 May. 29 at 5:53 PM
$CING I believe the 2:00 - 4:00 PM EST window is where we will hear something! Stay tuned
1 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers May. 29 at 5:48 PM
$CING Shorted more 4.30 here 5.05 avg + 4.30 1000 more shares CRL coming Monday Bating 8 for 8 on PDFUAs now after MKND approval See u all Monday Longs you should be aware this will go to 1$ +
4 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers May. 29 at 5:09 PM
$MNKD Nice win All out, now on to $CING CRL on Monday Lets make it 2 for 2 this week
3 · Reply
antant
antant May. 29 at 5:04 PM
$MNKD good job! time to move to $CING … pending event action on Monday
0 · Reply
kaos224
kaos224 May. 29 at 5:04 PM
$CING i didn't see pdufa for mnkd on FDA calendar
3 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers May. 29 at 4:36 PM
$MNKD MannKind got approved $CING CRL next. Lets make it 8 for 8
0 · Reply
PaulWalter
PaulWalter May. 29 at 4:21 PM
$CING The FDA are super overstretched. A couple of weeks delay would not surprise me at all.
1 · Reply
DelusionalOptionist
DelusionalOptionist May. 29 at 4:16 PM
$CING When do we get official news
0 · Reply
nik4
nik4 May. 29 at 3:35 PM
$CING Why ADHD Medications Have Higher CMC Risk ADHD reformulations face distinct technical challenges that draw intense FDA scrutiny: Complex Multi-Pulse Release Systems: Cingulate’s CTx-1301 relies on a sophisticated Precision Timed Release (PTR) triple-core tablet design. The FDA reviews these multi-layer coatings with a microscope to ensure that batch-to-batch consistency perfectly replicates the timed-release mechanism without "dose dumping" (releasing too much active drug at once). Controlled Substance Tightness: Because dexmethylphenidate is a Schedule II controlled substance, the DEA and FDA enforce incredibly tight tolerances on raw material accounting, active pharmaceutical ingredient (API) sourcing, and factory waste. This exact manufacturing anxiety is why the Polymarket prediction market for "Will the FDA approve Cingulate's CTx-1301" currently features an implied 61% probability of a 'No' (or delay).
0 · Reply
nik4
nik4 May. 29 at 3:25 PM
$CING When examining how often ADHD medications get hit with a Complete Response Letter (CRL) specifically due to manufacturing, chemistry, manufacturing, and controls (CMC), or facility issues, industry data reveals a clear and frustrating trend for biotech investors.Historically, roughly 74% of all CRLs issued by the FDA involve some form of CMC or manufacturing facility deficiency.
0 · Reply